Oxanthroquinone G01 is a potent inhibitor of KRAS and NRAS plasma membrane localization that potently inhibits proliferation of KRAS transformed cancer cells. Oxanthroquinone G01 also inhibits recycling of epidermal growth factor receptor and transferrin receptor, but has no influence on cholera toxin internalization. It also increases cellular levels of sphingomyelin and and ceramide.
potent inhibitor of KRAS and NRAS plasma membrane localization, putative RAS inhibitor
Storage Class Code
11 - Combustible Solids
WGK
WGK 3
Flash Point(F)
Not applicable
Flash Point(C)
Not applicable
Choose from one of the most recent versions:
Certificates of Analysis (COA)
Lot/Batch Number
It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documents section.
Chemical investigations of a soil-derived Streptomyces sp. led to the isolation of five new polyketides, (+)-oxanthromicin, (±)-hemi-oxanthromicins A/B, (±)-spiro-oxanthromicin A and oxanthroquinone, and the known alkaloid staurosporine, and the detection of four new metastable analogues, (±)-spiro-oxanthromicins B1/B2/C1/C2. Among the compounds
The Journal of biological chemistry, 293(35), 13696-13706 (2018-07-05)
Oncogenic RAS proteins are commonly expressed in human cancer. To be functional, RAS proteins must undergo post-translational modification and localize to the plasma membrane (PM). Therefore, compounds that prevent RAS PM targeting have potential as putative RAS inhibitors. Here we
Questions
Reviews
★★★★★ No rating value
Active Filters
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
